ArticleOncotarget2013
Enrichment of human osteosarcoma stem cells based on hTERT transcriptional activity.
Article in Oncotarget, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- Identification of STK35L1 as a potential prognostic biomarker in breast carcinoma, and its expression exhibits high correlation with EGFR activity.Functional & integrative genomics · 2026Article
- Inflammation-driven prognostic model and immune landscape profiling in osteosarcoma.Discover oncology · 2025Article
- Transcending frontiers in prostate cancer: the role of oncometabolites on epigenetic regulation, CSCs, and tumor microenvironment to identify new therapeutic strategies.Cell communication and signaling : CCS · 2024Review
- Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma.Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Reporter gene systems for the identification and characterization of cancer stem cells.World journal of stem cells · 2021Review
- Cancer Stem Cells as a Source of Drug Resistance in Bone Sarcomas.Journal of clinical medicine · 2021Review
- shRNA-mediated silencing of hTERT suppresses proliferation and promotes apoptosis in osteosarcoma cells.Cancer gene therapy · 2017Article
- Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity.Oncotarget · 2017Article
- miR-335 negatively regulates osteosarcoma stem cell-like properties by targeting POU5F1.Cancer cell international · 2017Article
- Cisplatin selects for stem-like cells in osteosarcoma by activating Notch signaling.Oncotarget · 2016Article
- Article
- Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies.Stem cells international · 2016Review
- Overcoming Therapeutic Resistance of Bone Sarcomas: Overview of the Molecular Mechanisms and Therapeutic Targets for Bone Sarcoma Stem Cells.Stem cells international · 2016Review
- Article
- Development of a Fluorescent Reporter System to Delineate Cancer Stem Cells in Triple-Negative Breast Cancer.Stem cells (Dayton, Ohio) · 2015Article
- Doxorubicin activates the Notch signaling pathway in osteosarcoma.Oncology letters · 2015Article
- TERT promoter mutations and telomere length in adult malignant gliomas and recurrences.Oncotarget · 2015Article
- Expression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma.Oncotarget · 2014Article
- TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas.Oncotarget · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Telomerase is crucial for the maintenance of stem/progenitor cells in adult tissues and is detected in most malignant cancers, including osteosarcoma. However, the relationship between telomerase expression and cancer stem cells remains unknown. We observed that sphere-derived osteosarcoma cells had higher telomerase activity, indicating that telomerase activity might be enriched in osteosarcoma stem cells. We sorted subpopulations with high or low telomerase activity (TEL) using hTERT transcriptional promoter-induced green fluorescent protein (GFP). The TELpos cells showed an increased sphere and tumor propagating capacity compared to TELneg cells, and enhanced stem cell-like properties such as invasiveness, metastatic activity and resistance to chemotherapeutic agents both in vitro and in vivo. Furthermore, the telomerase inhibitor MST312 prevented tumorigenic potential both in vitro and in vivo, preferentially targeting the TELpos cells. These data support telomerase inhibition as a potential targeted therapy for osteosarcoma stem-like cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.